Table 3: Logistic regression analysis for risk factors affecting seroconversion.

	Conversion to serotype 1	Conversion to serotype 3
Male sex	1·34 (0·36–4·92), 0·66	0·95 (0·32–2·83), 0·92
Rural setting, Matlab	0·96 (0·17–5·47), 0·96	6·19 (1·72–22·29), 0·01
Mother’s education <5 years	0·73 (0·20–2·66), 0·63	2·27 (0·76–6·75), 0·14
Moderate to severe stunting in any visit	0·39 (0·11–3·32), 0·81	0·64 (0·21–2·01), 0·44
Moderate to severe wasting in any visit	0·85 (0·22–1·38), 0·14	1·34 (0·38–4·71), 0·65
Exclusive breastfeeding at all visits	5·48(1·18–25·41), 0·03	0·86 (0·21–3·58), 0·84
Breastfeeding <15 min before giving OPV	0·81 (0·15–4·22), 0·80	0·49 (0·12–1·95), 0·31
High concentration of maternal antibodies for type-specific polioviruses, >1/72	0·35 (0·10–1·24), 0·10	0·11 (0·03–0·37), 0·0004
Received two or more doses of OPV during rainy months, June to September	1·06 (0·32–3·57), 0·92	0·36 (0·11–1·16), 0·09

Data are odds ratios (95% CIs), p values; obtained after three doses of tOPV (n=187). These were estimated controlling for all variables tested with univariate analysis and shown in the table (methods in appendix). OPV=oral poliovirus vaccine. tOPV=trivalent OPV.